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Abstract 
 
Nowadays, cancer is one of the leading causes of death worldwide and treatments currently 
in use are often aggressive, invasive and not very effective. Promising therapeutic approaches 
include immunotherapies that has the potential to boost the immune system to fight cancer.  
One type of immunotherapy is provided by vaccines of dendritic cells (DCs) or containing 
artificial antigen presenting cells (aAPCs). These vaccines are used to expand and activate T 
cells against specific tumors antigens, eliminating tumor cells and providing immunological 
protection. Activation of T cells in vivo is lead mainly by DCs. aAPCs are artificial systems that 
have as main goal to mimic the function that DCs have in vivo, by presenting antigens, the first 
signal required for T cell activation. Vaccines of aAPCs are easier to produce and maintain and 
overcome the issues of patient-derived autologous DCs. 
The main aim of this thesis was to implement an in vitro assay to test the potential of a new 
generation of aAPCs, named PEMs, to activate antigen specific human T cells. PEMs consist of 
carbonated cores assembled with HLA-A02 molecules loaded with peptides. 
To verify PEMs ability to activate T cells against a specific antigen (cytomegalovirus (CMV) 
peptide), PEMs were co-cultured with human CD8+ T cells, isolated from healthy donors. The 
activation of the cells was verified by the measure of the expression of IFN-γ  by qPCR and ELISA. 
Results showed that, in some donors, there is an increase of IFN-γ when T cells are 
stimulated with PEMs complexed with HLA-A02 loaded with CMV peptide, compared with 
negative controls. PEMs show significant binding to CD8+ T cells. 
With this study it was possible to conclude that PEMs are able to bind and activate T cells. 
However, there are still issues related to their stability and specificity. Future studies testing other 
aAPCs that present distinct cores and assemblies should be performed.  
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Resumo 
 
Atualmente, o cancro é uma das principais causas de morte no mundo e os principais 
tratamentos que são utilizados são frequentemente agressivos, invasivos e pouco eficazes. 
Abordagens terapêuticas promissoras incluem imunoterapias que têm o potencial de impulsionar 
o sistema imunológico para combater o cancro.  
Um tipo de imunoterapia é fornecido por vacinas de células dendríticas (DCs) ou que contém 
células artificiais apresentadoras de antigénios (aAPCs). Estas vacinas são usadas para 
expandir e ativar as células T contra antigénios tumorais específicos, eliminando células tumorais 
e fornecendo proteção imunológica. A ativação de células T in vivo é conduzida principalmente 
por DCs. aAPCs são sistemas que têm como principal objetivo imitar a função que as DCs têm 
in vivo, apresentando antigénios, o primeiro sinal necessário para a ativação das células T. 
Vacinas de aAPCs são mais fáceis de produzir e manter e permitem ultrapassar os problemas 
de DCs autólogas derivadas de pacientes. 
O principal objetivo desta tese foi implementar um ensaio in vitro para testar o potencial de 
uma nova geração de aAPCs, denominadas PEMs, para ativar células T humanas específicas 
para determinados antigénios. PEMs consistem em núcleos de carbono ligados a moléculas de 
HLA-A02 carregadas com péptidos.  
Para verificar a capacidade das PEMs para ativar células T contra um antigénio específico 
(péptido do citomegalovirus (CMV)) as PEMs foram co-cultivadas com células T CD8+ humanas, 
isoladas de dadores saudáveis. A ativação das células foi verificada pela medição da expressão 
de IFN-γ por qPCR e ELISA.  
Os resultados mostraram que, em alguns dadores, houve um aumento de IFN- quando as 
células T foram estimuladas com PEMs complexadas com moléculas de HLA carregadas com o 
péptido CMV, em comparação com os controlos negativos. PEMs mostram ligação significativa 
às células T CD8+. 
Com este estudo foi possível concluir que as PEMs podem ligar-se e ativar células T. 
Contudo ainda existem questões relacionadas com a sua estabilidade e especificidade. Futuros 
estudos, que testem outras aAPCs que apresentem outros núcleos e formas devem ser 
realizados.  
 
Palavras-chave: Cancro; Imunoterapias; Células T; APCs; aAPCs 
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1 Introduction 
1.1 Immunity, immune system and immunology 
Immunity is defined as resistance to diseases, more specifically to infectious diseases [1].  
The immune system involves many organs, molecules, cells and pathways in interconnected 
processes and has evolved as the host’s defense, to protect multicellular organisms from 
pathogens and cancer [2], [3]. 
Immunology is the study of the immune system and the responses to the invading pathogens 
microorganisms. The reaction of the components of the immune system against infectious 
microorganisms is known as the immunologic response [1].  
In vertebrates the immunologic defenses are divided into two immunologic subsystems – the 
innate and adaptative immune responses [4]. 
 
1.1.1 Innate immunity 
Innate immunity is the first line of defense and it is found in all multicellular plants and animals 
[5]. It works rapidly (in some hours) against the infectious insult and gives rise to the acute 
inflammatory response. When a host is attacked by a pathogen it is the innate immune system 
that responds with immediate action. In the innate immune system are included the epithelial 
barriers, specialized cells and natural antibiotics that block the entry of the microorganisms in the 
epithelia [2]. In the tissues or in the circulation, the microorganisms are destroyed by the 
phagocytes (macrophages and neutrophils), the natural killer (NK) cells and also plasmatic 
proteins, where the complement system is included. This type of immunity has some specificity 
for microbes but no memory [5], [6]. 
The innate immune system recognizes the pathogens through pattern-recognition receptors 
(PRR). These receptors identify particular types of molecules that are common to many 
pathogens, known as pathogen-associated molecular patterns (PAMPs), that do not exist in the 
host [7], [8]. The lipopolysaccharide (LPS), a component of the Gram-negative bacteria cell wall 
(recognized by the toll-like receptor 4 (TLR-4)) and the teichoic acids on Gram-positive bacteria 
are examples of PAMPs [8], [9]. Different PRR recognize specific PAMPs which will activate 
specific signaling pathways leading to different responses against pathogens [7], [8]. 
 
1.1.2 Adaptive immunity  
In addition to the innate immune responses, vertebrates also have an adaptive immunity. 
The adaptive immune responses are the second line of defense and are highly specific to a 
particular antigen [10]. This type of immunity takes more time to be effective, usually days, since 
the organism is first exposed to the antigen, but provides long-lasting protection mediated by cells 
and molecules forming the immunologic memory. Innate immune responses are responsible for 
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activating adaptive immunity and together they work in order to eliminate the foreign molecules. 
B and T lymphocytes are white blood cells that are responsible for the adaptive immune 
responses. There are two types of adaptive immunity, the humoral responses and the cell-
mediated immune responses [10]–[12]. 
B cells are involved in the humoral responses. In this type of response, B cells are activated 
and differentiate into plasma cells, producing antibodies, which are proteins that will destruct 
microorganisms in extracellular spaces. Activation of B cells is stimulated by specific soluble 
antigens, and the antibodies produced specific for that antigens. The antibodies binds to the 
pathogens blocking them or mark them for destruction that is carried out mostly by phagocytic 
cells [10][13]. 
T cells are responsible for cell-mediated immune responses. T cells are activated when 
antigen presenting cells (APCs) present the antigen to the T cell in the context of major 
histocompatibility complex (MHC). Dendritic cells are professional APCs which ingest the 
antigens and then present them. Activated T cells can destroy directly the infected cells (effector 
T cells) or they can produce molecules that will activate macrophages and promote the 
phagocytosis (helper T cells) [10][14]. 
 
1.1.3 T cells 
Lymphocytes are developed in lymphoid organs. T lymphocytes are derived from stem cells 
in the bone marrow but their development occurs mainly in the thymus. The immature T cells 
derived from bone marrow migrate towards the thymus where maturation takes place. Interactions 
between immature T cells and thymic stromal cells lead to the differentiation and posterior 
proliferation of T cells. The development of T cells occurs in different phases and in each phase 
occurs changes at T cell receptor (TCR) genes and expression levels. [15][16] 
TCR is a disulfide-linked heterodimeric protein that is attached to the membrane. These 
protein is typically constitute by a complex with two different parts. One part consisting of the 
highly variable α and β chains and the other part is constitute by the invariant CD3 chain 
molecules.[16] 
Majority of T cells express the α and β chains (α:β T cells) but there is a minority that express 
an alternate receptor that is formed by variable chains γ and δ (γ:δ T cells). During TCR 
development occurs a specific process of gene recombination in somatic T cells. TCRα gene 
locus contains variable (V) and joining (J) gene segments and TCRβ contains, beside V and J 
segments, a D (diversity) gene segment. Therefore, α chain is generated from VJ recombination 
and β chain from VDJ recombination. In γ:δ TCRs the process is similar since VJ recombination 
is involved in γ and δ chain is generated from VDJ recombination. [17], [18] 
During maturation, cell-surface proteins expression is altered, mainly involving the TCR 
(CD3) complex expression and CD4 and CD8 proteins. Mature T cells express a diverse of 
antigen specific receptors - T cell receptors, due to the rearrangement of the genes that encode 
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to the antigen receptors and the changes of expression that happen in cell-surface and 
intracellular proteins. [15] 
In the last phase of development, α:β T cells originate two types of cells - CD4+ and CD8+ T 
cells, which are functionally different. Cells where the rearrangements do not occur properly die 
by apoptosis.[16] 
TCR recognize only antigens that are bound to MHC molecules in the surface of APCs. CD4+ 
T cells are called helper cells because they provide signals and cues to B lymphocytes in antibody 
productions and to phagocytic cells in their function. CD8+ T cells are named cytotoxic T cells 
since they kill infected or aberrant cells. [1] 
 
1.1.4 T cell activation 
To activate T cells, three different signals are required. Signal 1 occurs when an APC 
presents an antigen on the surface bound to MHC molecules, to be recognized by the TCR. 
Furthermore, CD4 molecules on helper T cells and CD8 molecules on cytotoxic T cells will bind 
to MHC II and MHC I on APC, respectively. This selective recognition is termed MHC restriction. 
These interactions between TCR and peptide-MHC complexes and between CD4 or CD8 and 
MHC II and MCH I will induce a cascade of signaling from the cytosol to the nucleus. This cascade 
of events involves many interactions and modifications on proteins, such as phosphorylation and 
ubiquitination, interacting with many second messengers, like calcium and diacylglycerol. It is a 
fact that TCR recognize the antigens that allow a specific response. [19]–[22]  
Signal 2 is co-stimulation, where the costimulatory molecules from APC bind to co-receptors 
on the surface of the T cells. If co-stimulation does not occur, T cells can recognize the antigen 
but they cannot respond and die or enter in a state of anergy (unresponsive state) [20]. The best 
known T cell costimulatory pathway involves the costimulatory molecules B7-1 (CD80) and B7-2 
(CD86) expressed on APCs and the CD28 receptor expressed on T cells. Pathogens and 
cytokines enhance the expression of costimulatory molecules in the surface of APCs. Signal 1 
and 2 promote the expansion of T cells which were stimulated, and their subsequent 
differentiation in effector and memory cells. CD28 receptor induce the production of cytokines, 
especially of interleukin-2 (IL2). These cytokines promote metabolism and up-regulation of cell-
survival genes [20], [21], [23]. 
However, there are also signaling molecules driving inhibitory responses. Cytotoxic T 
lymphocyte associated antigen 4 (CTLA-4) is one of those molecules and it can bind to B7-1 and 
B7-2, since it is a homologue of CD28. CTLA-4 is a negative regulator of T cell activation while it 
is expressed in activated T cells. When expression of CTLA-4 is upregulated, the expression of 
CD28 is downregulated by endocytosis and CTLA-4 can bind to the costimulatory molecules on 
APC and inhibit the T cell responses, by blocking the production of IL-2 and the progression of 
cell-cycle [20], [23]. 
Also, the expression of costimulatory molecules B7-1 and B7-2 is regulated on the APCs 
being dependent of the activation state of the cell. Transcription, translation and trafficking of B7-
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1 and B7-2 to the surface of APCs are enhanced by the recognition of infection and stress and 
cellular levels by innate receptors. This regulation is essential to prevent aberrant and 
autoreactive T cell responses allowing the responses against non-self antigens [20]. 
Signal 3 is provided by cytokines produced by macrophages and dendritic cells, and is 
required for the effective production of effector and memory cells as well as for the survival of T 
cells. The knowledge about this third signal of stimulation is recent and the cells that do not receive 
this signal do not develop cytolytic function and stay unresponsive. Cytokines that provide signal 
3 are essentially IL-12, interferon (IFN)-α, IFN-β and IL-21 [20], [24]. Figure 1.1 illustrates the 
three signals needed for T cell activation.   
 
 
 
 
 
 
 
 
 
 
Figure 1.1 - Three signals for T cell activation. Interaction between dendritic cells and T cells for T 
cell activation involves three signals. Signal 1 consists in the interaction between MHC containing peptide 
fragments on DC and the TCR on the T cell. Signal 2 is provided by the interaction between co-stimulatory 
molecules on DC surface and their receptors on T cell surface. Signal 3 occur when DC secrete IL-12.  
Adapted from [25]. 
 
1.1.5 T cells differentiation after activation 
After activation of T cells, they can differentiate essentially in two types: helper T cells (CD4) 
and cytotoxic T cells (CD8). Helper cells are responsible for production of cytokines, that activate 
other cells, and chemokines that recruit other cells to the place of infection. The main function of 
cytotoxic cells is the killing of pathogen infected cells by delivering cytotoxic granules in their 
cytosol. As there is a very diverse number of pathogens, the host produces different specialized 
T cells responses specific for the invading pathogen. Helper T cell responses are divided into 
different subsets depending on the pathogen, being the major ones Th1, Th2 and Th17 subsets. 
In the Th1 subset there is the production of large amounts of IFN-γ and tumor necrosis factor 
(TNF) α in response to intracellular pathogens such as virus. The Th2 subset is characterized by 
the production of large amounts of IL-4, IL-5 and IL-13 which will activate eosinophils, mast cells 
and basophils to eliminate parasites [26]. In order to eliminate extracellular bacteria and fungi, 
Th17 subset is activated and these cells produce IL-17. This cytokine is responsible for the 
activation of neutrophils which have the ability to kill bacteria and fungi [27]. Cytotoxic T cells are 
responsible for elimination of intracellular pathogens and cancer cells and they are activated after 
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they recognize their antigens in the presence of cytokines (IFN-α, IFN-β and IL-12). After 
activation cytotoxic T cells produce large amounts of IFN-γ, TNF-α and secretory vesicles that 
contain perforin and granzyme proteins that have the ability to kill the other cells and disseminate 
close to them [21]. 
 
1.1.6 Antigen presenting cells (APCs) 
APCs are cells that are able to capture antigens, process them into peptides and present 
them to lymphocytes to activate them. DCs, macrophages and B cells present antigens mainly to 
T cells and are considered professional APCs since they express MHC II and co-stimulatory 
molecules [28]. However, there are other cells that can also present antigens such as thymic 
epithelial cells and vascular endothelial cells. In the lymph nodes, follicular dendritic cells act as 
APCs for B cells. APCs present antigens in form of peptide-MHC complexes. To present antigens 
to a CD4+ T cell, the presentation is made in association with MHC II. If an antigen is to be 
presented to  CD8+ T cells, APCs do it via MHC I [28], [29]. 
DCs are the most potent because  are the only APCs capable of activating naïve T cells, and 
also because they can present antigens either via class I or class II MHC molecules activating 
CD4+ and CD8+ T cells. [30] They also present a constitutive expression of B7 co-stimulatory 
molecules. Costimulatory molecules are essential to a properly activation of T cells as mentioned 
before. [28] 
DCs capture antigens that invade the organism by phagocytosis, micropinocytosis or 
endocytosis[3]. DCs reside in certain areas of epithelial tissues and express receptors that bind 
directly to microorganisms and mannose residues on glycoproteins (bacterial characteristic). After 
recognition, the antigens are mainly captured by endocytosis. Besides endocytosis, antigens can 
bind also to TLRs on DCs and macrophages, enhancing the production of TNF and IL-1. 
Altogether, these factors contribute to activate DCs, inducing their migration towards lymph nodes 
in response to chemokines. In the lymph nodes, they can activate T cells. During migration DCs 
become mature and start to express costimulatory molecules and MHC molecules in a stable way 
[28], [31]. 
 
1.1.6.1 Antigen Processing and Presentation 
 
To activate T cells, antigens need to be presented by APCs in form of peptides-MHC 
complexes or lipid-CD1 molecules complexes. In humans, MHC is designated by human 
leukocyte antigen (HLA). APCs express MHC II in their native state, while MHC I is expressed in 
all nucleated cells (including APCs). There are two major pathways responsible for the processing 
and presentation of antigens. One of the pathways is related to processing extracellularly-derived 
proteins (exogenous), presenting them via MHC II , while the other pathway presents cytosolic 
proteins (endogenous) via MHC I. [32] 
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However, DCs are also capable of process and present extracellular antigens via MHC I 
through cross-presentation. There are two main intracellular pathways for cross-presentation.[33]  
Cytosolic pathway involves the uptake of exogenous antigens and their transport from endosomal 
vesicles into the cytosol. In the cytosol, antigens are degraded by the proteasome and then 
transported by a transporter associated with antigen processing (TAP) into the endoplasmic 
reticulum (ER) where they are loaded on MHC I molecules.[34]–[36] 
Vacuolar pathway is independent of proteasome since capture antigens are processed by 
endosomal proteases and load on MHC I in endosomal compartments. [34]–[36]  
 
1.1.6.2 MHC II/Endocytic Pathway 
 
Endocytic pathway (Figure 1.2) is responsible for processing the proteins that enter in the 
cell by endocytosis, phagocytosis or pinocytosis. These proteins are internalized in phagosomes, 
that fuse with lysosomes creating phagolysosomes where proteins are processed by proteolytic 
enzymes. This enzymatic cleavage generates a diverse array of peptides. [37] 
MHC II molecules synthesized in the ER have the peptide-binding site blocked by the 
invariant chain (li). After synthesis, MHC II molecules are secreted in vesicles that posterior will 
fuse with the phagolysosomes where the peptides were processed. There the invariant chain is 
broken leaving only a small fragment called class II-associated invariant chain peptide (CLIP) that 
blocks the peptide-binding site. Then CLIP is removed by an MHC II-like structure and MHC II 
can bind to the peptides and migrate into exocytic vesicles to the cell surface in order to present 
the antigen to CD4 cells.[32], [38]  
 
Figure 1.2 - MHC II/Endocytic pathway for intracellular processing of proteins antigens. Protein 
antigens found in endocytic vesicles are converted into peptides that bind to MCH II molecules for recognition 
by CD4+ T cells. Adapted from [5]  
 
1.1.6.3 MHC I/Cytosolic Pathway 
 
The cytosolic pathway (Figure 1.3) is responsible for processing proteins generated in the 
cytosol, such as viral proteins in infected cells or native proteins from the cell that are aberrantly 
synthesized or no longer needed. All these proteins are ubiquitinated and degraded in the 
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proteasome and then translocated by TAP from the cytosol to the ER, where they are combined 
with MHC I molecules.[39] 
MHC I molecules, synthesized in the ER, are constitute by a polymorphic heavy chain and a 
chain called β2-microglobulin. In the ER, MHC I molecules without peptides are stabilized by 
chaperone proteins and the association of MHC I/β2-m heterodimers. When the right peptide finds 
the right MHC I, they form a non-covalent complex and MHC I becomes stable. The complex 
peptide-MHC I then migrates to the cell surface through the trans-Golgi network in order to 
present the antigen to CD8+ cells [32], [38] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 - MHC I/Cytosolic pathway for intracellular processing of proteins antigens. Cytosolic 
proteins are converted into peptides that bind to MHC I molecules to be recognize by CD8+ T cells. Adapted 
from [5] 
 
1.2 Cancer 
Cancer is one of the leading causes of death worldwide along with cardiovascular, chronic 
lower respiratory and neurodegenerative diseases and diabetes [40]. In general, 1 in 6 deaths 
are caused by cancer and it is expected that in the next two decades the number of new cases 
will increase by about 70%. Neoplasms of lung, liver, colorectal, stomach and breast are the most 
common [41]. Cancer results from genomic modifications in normal cells that turn them into tumor 
cells. These alterations consist on the accumulation of somatic mutations that lead to uncontrolled 
growth and proliferation of the mutated cells. Some of these alterations are related to the 
interaction between genetic factors and external factors, which include physical carcinogens (e.g. 
ultraviolet and ionizing radiation), chemical carcinogens (e.g. aflatoxin and arsenic) and biological 
carcinogens (e.g. infections by certain viruses, bacteria or parasites). More common mutations 
that lead to cancer are those that occur in genes responsible for deoxyribonucleic acid (DNA) 
repair, in proto-oncogenes and tumor suppressor genes. Mutations in proto-oncogenes lead to 
production of oncogenes with dominant gain of function and mutations in tumor suppressor genes 
lead to a recessive loss of function  [40]–[42]. 
All these changes can occur in any cell of the body, leading to different types of cancer. Each 
neoplasm has a different behavior and that’s why each type responds differently to treatments. 
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Tumor growth can be benign or malignant. In general, benign tumors remain confined to their 
original location; otherwise, in malignant tumors, abnormal cells can invade surrounding normal 
tissues and also spread to other organs via circulatory or lymphatic systems in a process called 
metastasization, being metastases the major cause of death from cancer [41].  
Depending on the type of cell from which tumors arise they are classified into: carcinomas, 
originating from epithelial cells; sarcomas, that arise from connective tissues and are relatively 
rare in humans; leukemias that arise from blood forming cells and lymphomas that arise from 
immune system cells [42], [43]. 
Tumors consist of complex tissues formed by multiple distinct cell types that interact between 
themselves. Cancer cells and the tumor microenvironment contribute to many of the hallmark 
capabilities that tumors present. Cancer hallmarks (Figure 1.4) consist of acquired capabilities of 
cancer cells that allow them to survive and proliferate. Cancer cells can be self-sufficient in growth 
signals and insensitive to anti-growth signals because many cell survival and proliferation 
signaling pathways are deregulated, thus allowing cancer cells to maintain a chronic proliferation. 
These cells can avoid apoptosis may present a limitless replicative potential due to their ability to 
maintain telomeric DNA at lengths that avoid apoptosis. Angiogenesis, tissue invasion and 
metastasis are also typical abilities of tumor cells. Angiogenesis is triggered by hypoxia and allows 
cancer cells to obtain nutrients and oxygen. Other hallmarks may consist on evading the immune 
system through genetic and epigenetic modifications and reprograming energetic metabolism 
pathways, which is related to the fact that tumor cells can limit their energy metabolism to 
glycolysis even in the presence of oxygen leading to a state of aerobic glycolysis (Warburg effect) 
[44], [45]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Hallmarks of Cancer. Functional capabilities acquired by cancer during their 
development. Adapted from [44] 
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1.2.1 Cancer treatment  
 There are many types of treatment options for cancer patients and the treatment that 
each patient receives is related to the type of cancer and how advanced it is. Most of cancer 
patients receive a combination of treatments. Currently, combination of surgery with 
chemotherapy and/or radiotherapy is the most common treatment regime. Surgery is considered 
the best procedure for solid tumors that are confined to a specific area [46]. With surgery, it is 
possible to remove the entire tumor in some cases. In other cases, when the removal of the entire 
tumor can cause damage in an organ, the tumor should be debulked, which means that part of 
the tumor, but not all, is removed. Sometimes, surgery is only used to remove tumors that are 
causing pain to the patients [46] 
Radiotherapy uses high doses of radiation to kill cancer cells and chemotherapy uses drugs 
to kill cancer cells. Radiotherapy and chemotherapy not only kill cancer cells, but these therapies 
also have the potential to kill healthy cells. This causes side effects like nausea, hair loss and 
mouth sores [47]. 
More recently, new and more specific therapies have been developed, such as 
immunotherapy, targeted therapy, hormone therapy and stem cell transplant. Immunotherapy is 
a biological therapy in which substances made from living organisms (or cells itself) are used to 
treat cancer. In immunotherapy, the host immune system is helped to fight cancer. 
Immunotherapies include the ones where cancer cells are marked to be easier for the immune 
system to find and kill them, usually by antibodies, and the ones where the immune system is 
boosted to be easier the fight against cancer. Targeted therapy consists of the design of 
essentially small molecule drugs or monoclonal antibodies which will target the changes in cells 
that lead to cancer and block their effects. Hormone therapy uses hormones in order to slow down 
or stop cancer from progressing. This type of therapy is essentialy used in prostate and breast 
cancers since they are hormone-sensitive to grow. In patients who receive systemic 
chemotherapy or radiotherapy to treat cancers, the blood cells are usually destroyed. In this case, 
a stem cell transplant can be performed in order to restore blood-forming stem cells, since all 
types of blood cells are important to the health of the organism. [47] 
 
1.2.2 Cancer immunotherapy 
Cancer immunotherapy involves the use of components of the immune system in order to 
treat cancer patients. Immunotherapy against cancer has the purpose to kill cancer cells by 
activating the immune system against these cells either passively or actively. Passive 
immunotherapy is related to, for example, monoclonal antibodies which are designed to recognize 
specific targets expressed by the tumor cells or existing in the tumor microenvironment. In this 
type of therapy, there is a higher specificity and off-target toxicities can be avoided. In contrast, 
active immunotherapy is related to the stimulation of immune cells to fight cancer. In this case, 
immune cells, especially T cells and B cells, are stimulated for a specific antigen. In fact, the 
knowledge that T cells are able to recognize specifically cancer cells and kill them is exploited in 
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this case. Accordingly, it is possible to produce a large number of activated T cells specifically 
against tumor antigens, eliciting the elimination of cancer cells. Adoptive T cell transfer is based 
on the same scheme: T cells isolated from cancer patients are stimulated with tumor antigens 
and expanded ex vivo, for later reinfusion into patients. After reinfusion, T cells will respond to 
cancer cells by killing them [48][49]. 
Chimeric antigen receptor (CAR) T-cell therapy is one specific type of adoptive T cell transfer 
therapy with leading results in the field and tested in small clinical trials. In this particular therapy, 
white blood cells are removed from patients and then T cells are separated and genetically 
modified. The modification consists of the addition of the specific CAR which will recognize a 
specific tumor antigen. After expansion of CAR T-cells, they are reintroduced into patients, 
specifically targeting cancer cells [49]. 
Cytokines, especially interferons and interleukins, are also used to treat cancer. These 
molecules are produced by the host own cells and have a key role in normal immune responses 
and in the response of the immune system against cancer [48]. 
Treatment vaccines against cancer are other type of immunotherapy. In this case there is a 
boost of the immune systems in order to respond to cancer cells [48]. 
One type of anti-tumor therapeutic vaccines is the one where patients are vaccinated with 
DCs, expanded and activated ex vivo, promoting and improving the activation of T cells. Since 
this process is expensive and time consuming, and the DCs generated can present a variable 
quality, other methods to activate T cells are starting to appear in the experimental setting. 
Artificial antigen presenting cells (aAPCs) are a new method that has been used to activate 
specifically T cells against tumor antigens either ex vivo or in vivo [50]. 
 
1.3 Artificial antigen presenting cells (aAPCs) 
aAPCs are engineered systems for activation and expansion of T cells, mimicking the role 
of DCs. These systems include engineered cells or synthesized biomaterials and they have the 
advantage of being more controlled and reproducible [50], [51]. However it is very important to 
consider some variables when aAPCs are designed. These variables include the size, shape, 
mechanism for cytokine delivery and ligand distribution, mobility and positioning on aAPCs. All 
these factors will influence T cell activation. Most aAPCs are spherical particles which may be a 
disadvantage since DCs (natural APCs) are not spherical and for that reason have a bigger 
contact area with T cells than aAPCs.  
The use of aAPCs has become a successful tool in immunology and clinical applications, 
especially the ones made with biomaterials which generate anti-tumor immune responses both in 
vitro and in vivo. Some advantages of these systems are the fact that they are not time-consuming 
in manufacture or preparation and they do not need expensive cell-culture strategies.[50], [52] 
In these type of systems, the three signals that are needed for T cell activation are mimetized 
usually using agonist molecules. For example, signal 1 is provided by TCR agonists, such as 
recombinant peptide-MHC complexes or antibodies that are directed to CD3. Signal 2 is co-
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stimulation and it is provided by co-stimulatory agonists, for example anti-CD28 monoclonal 
antibodies. Cytokines are responsible for signal 3 and they play an important role in T cell 
expansion and differentiation. IL-2 is the cytokine most commonly used to guarantee signal 3 
since it is the best known for the survival of CD8+ T cells. However, there are other cytokines that 
can promote, even better, expansion and differentiation of T cells. In these group of cytokines are 
included IL-7, IL-15 and IL-21.[53], [54]  
Currently, there are some clinical trials where aAPCs have been tested. For example, anti-
CD3/anti-CD28-coated magnetic beads, a type of aAPCs, have been applied in Phase I clinical 
trials. These aAPCs were tested in patients with metastatic breast cancer, chronic myeloid 
leukemia and carcinomas. These trials showed, in some cases, tumor regression or even 
complete remission but also showed a risk of developing graft versus host disease or non-tumor-
specific cytotoxicity [50].  
Silica microspheres containing peptide-MHC I complexes or tumor cell membranes were 
tested first in mice where they induced regression of tumors in combination with chemotherapeutic 
agent cyclophosphamide. In Phase I and II clinical trials these aAPCs were tested in patients with 
melanoma and renal cell carcinoma. It was observed a variable success where partial responses 
were induced, in some cases [50]. 
 
1.3.1 Cell Based aAPCs 
There are aAPCs based on xenogenic or allogenic cells genetically modified, such as 
Drosophila cells, murine fibroblasts and human erythroleukemia cells (K562) [55]. These cellular-
aAPCs present several advantages, since these are stable cell lines that can be easily handled, 
stored for long periods and easily obtained. Cells used in this system are also better defined than 
DCs, which allows a more controlled system. The biggest disadvantage is related with the 
allogenic nature of cells.[50], [55] 
To be used as aAPCs, cells are engineered by transduction with retroviral or lentiviral 
vectors. Transduction allows introduction of necessary molecules needed for the immune 
synapse formation, such as TCR, costimulatory and adhesion molecules. Besides these, 
cytokines can be introduced in culture medium or produced by cellular-aAPCs.[55], [56] 
 
1.3.2 Synthetic/Acellular aAPCs 
Acellular aAPCs are relatively easy to prepare, provide a more stringent control when 
compared to cellular aAPCs and can be nonspecific or antigen-specific because they can activate 
T cells either presenting T cell activating antibodies, such as anti-CD3, or presenting specific 
peptide-MHC complexes. Most of aAPCs approaches use MHC stimulation for CD8+ T cells 
activation, since these cells have antigen specific tumor cell lysis ability. There are some 
properties of aAPCs that will influence T cell activation. Size, shape, distribution of ligands in the 
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surface and ligand mobilities are some of those properties. Therefore, many types of aAPCs have 
been developed in order to understand which ones are better to mimic DCs.[50], [52] 
Currently there are many systems of synthetic aAPCs being developed. These systems are 
based on synthetic and biomimetic biomaterials and they present applications in immunotherapy 
either ex vivo and in vivo.[53] 
Liposomes, RAFTsomes and microdomain liposomes are lipid based aAPCs which are 
particles with a lipid bilayer and a fluid membrane. Liposomes containing MHC were developed 
by Prakken et al., and were able to activate CD4+ T cells in vitro [57]. Ding et al. developed the 
RAFTsomes which are liposomes containing pre-clustered peptide-MHC complexes on 
membrane microdomains. These ones were capable of promoting CD4+ T cell proliferation [58]. 
Giannoni et al. described other systems based on artificial membrane bilayers containing T cell 
ligands membrane microdomains [59]. Since liposomes are poorly stable, some scaffolds started 
to be used. These scaffolds have as main function to support the lipid bilayers and improve the 
advantages of using these systems as aAPCs. Lipid bilayers were constructed on Poly(lactic-co-
glycolic acid) (PLGA), silica or core of hydrogel.[53] 
Polymeric aAPCs are another type of aAPCs that are made from polymers. The most 
common used polymers PLGA, sepharose or polystyrene beads. The polymeric particles present 
immunomodulatory compounds (anti-CD3, anti-CD28, peptide-MHC complexes) on the surface 
and can release gradually the IL-2 or other soluble molecules that were encapsulated inside. In 
this case, the optimal size of microbeads was between 4 to 5 μm. [50] 
Since natural APCs are not spherical and the shape is a very important parameter for T cell 
activation, there were also designed non-spherical microparticles. Ellipsoid PLGA microparticles 
made using film-stretching technologies are one of these examples. Like this, it is possible to 
better mimic what happens in vivo. [50], [53] 
Carbon nanotube bundles, other type of aAPC, are functionalized nanotubes coated with 
anti-CD3 that seem to be grouped into large aggregates with a high surface area which contribute 
to a better T cell activation. [53] 
Nanoworms are aAPCs that combine two important aspects, membrane fluidity and shape, 
to access better results. For this, semi-flexible filamentous polymers are used to form the 
nanoworms that, then, can be decorated with antigen presenting and co-stimulatory 
molecules.[50] 
There are also aAPCs that contain magnetic parts. Levine et al. describe magnetic beads 
linked to anti-CD3 and anti-CD28 antibodies. These beads were applied in clinical trials as a 
potential treatment for different types of cancers. [53] 
 
1.3.3 Polyelectrolyte Microcapsules (PEMs) 
Polyelectrolyte Microcapsules (PEMs) are a type of synthetic aAPCs that were produced at 
Sebastian Springer’s laboratory in Jacobs University at Bremen, Germany and their performance 
was tested in the context of this thesis.  
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PEMs are carbon microcapsules that were produced using calcium carbonate particles with 
5-6 μm of size. The calcium carbonate particles were coated with two layers of PAH 
(Poly(allylamine hydrochloride)) and PAA (Poly(acrylic acid) sodium salt) in alteration. After that, 
the –COOH groups on the microcapsules were activated with EDC (1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimid) and Sulfo-NHS (Sulfo N-Hydroxysuccinimide) and the 
streptavidin molecules were added in order to coat the PEMs [60]. 
 
1.4 Aim of Thesis 
Cancer vaccines are one type of immunotherapy, especially vaccines of DCs. More recently, 
aAPCs have been developed in order to increase the safety and efficacy of treatment. In the last 
case, aAPCs are used to expand and activate T cells against specific tumor antigens.  
The main aim of this thesis is to test a new generation of aAPCs and to study their potential 
to activate T cells in vitro (Figure 1.5). aAPCs tested in this thesis were microcapsules made and 
assembled by researchers at the Jacobs University and named PEMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 - One strategy of cancer immunotherapy. Activation of T cells isolated from patients can 
be induced by aAPCs. Adapted from [50]. 
PEMs microcapsules have a carbonate core and are coated with streptavidin molecules. In 
addition to PEMs, three types of HLA-A02 molecules biotinylated were used in this thesis: HLA-
A02 molecules with no peptide (empty), with NV9 peptide, which is a peptide derived from 
cytomegalovirus (CMV), and also HLA-A02 molecules with IV9 peptide, a peptide derived from 
proteins of the human immunodeficiency virus (HIV). Since HLA-A02 molecules were biotinylated 
and PEMs were coated with streptavidin it was possible to bind the two components by a 
streptavidin-biotin reaction.  
HLA-A02 molecules were used as a model because this allele is one of the most prevalent 
in the population. The CMV peptide was chosen as the peptide of interest since 60% to 90% of 
the adults have suffered a CMV infection at some point in their life [61]. The HIV peptide was 
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chosen as peptide of control since the cells used in the tests were from healthy donors tested for 
HIV. 
In order to test the capacity of PEMs to activate T cells, co-cultures of CD8+ T cells and 
PEMs were made. Since all of the technical system was optimized with HLA-A02 molecules, the 
T cells used in co-cultures had to be T cells isolated from HLA-A02 positive donors. The first step 
was to perform a screening of HLA-A02 positive donors by flow cytometry. After that, T cells were 
isolated from positive donors by a density gradient in Biocoll. To test if PEMs were capable to 
activate T cells, the co-cultures were maintained for different time points. To test the activation of 
T cells the expression of IFN-γ was evaluated at transcriptional and protein level. 
 Since PEMs technology use CMV peptide as peptide of interest, only the CD8+ T cells from 
donors previously infected with CMV and with lymphocytes responsive to CMV will produce IFN-
γ in response to the stimulus.  Figure 1.6 represent a schematic resume of the principal steps and 
methods used in this thesis to achieve the aim. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 - Schematic resume of the aim of the thesis. Principal steps and respective methods 
used. First step consists in screening of HLA-A02 positive donors by flow cytometry. Second step consists 
in the isolation of CD8+ T cells by density gradient and then co-culture of the isolated cells with PEMs. Final 
step was testing the activation of T cells measuring the expression of IFN- by RT-PCR and ELISA. 
 
Test activation of T cells by measuring expression of IFN- γ
RT-PCR and ELISA
Co-culture of CD8+ T cells with PEMs
Isolation of CD8+ T cells
Density Gradient
Screening of HLA-A02 positive donors
Flow cytometry
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2 Materials and Methods 
2.1 Flow cytometry 
Flow cytometry is a sophisticated and powerful tool that allows a rapid analysis of multiple 
individual parameters of single cells, or other particles such as nuclei, microorganisms, 
chromosome preparations and latex beads. This technique allows to measure the optical and 
fluorescence characteristics of a suspension of particles [62], [63]. 
Flow cytometers are composed by three principal components: fluidics, optics and 
electronics. The fluidic system introduces and aligns the particles in a continuous flow in direction 
to the laser beam allowing a single cell or particle to go through the light laser. The optical system 
is divided into excitation components and collection components. The first one is responsible for 
focusing the light source on the particles and the collection components capture the dispersion 
and emitted fluorescent light by the fluorophores that are excited by the laser beam. This 
information is transmitted to the electronic system that converts the signal into digital data.[64] 
In flow cytometers, the particles pass one by one through a laser beam and the scattered 
lights at different angles (related with structure and morphology of the cells) and fluorescence 
emissions are measured. Size, granularity, which are related with the internal complexity of the 
cell, and fluorescent features are physical properties that are used to characterize and 
differentiate cell populations.[65] 
The forward angle light scatter (forward-scatter) is related with the size of the cells and the 
complexity of the cells is represented by the right angle scatter and it is known as side-scatter.[63] 
The fluorescent emissions which are measured can be derived from natural or chemical 
molecules. The last ones are used to stain some components that do not have natural 
fluorescence.[64] 
Fluorescent compounds absorb light energy over a range of specific wavelengths. This 
absorption allows an electron to move into its excited state, as it passes from its fundamental 
level of energy to a higher energy level. Once the excited electron quickly returns to its ground 
state the excess of energy is released as a photon of light, being this release of energy called 
fluorescence. [62] 
The fluorescent dyes can bind to different cellular components and antibodies conjugated to 
fluorescent dyes can bind with more specificity to the cellular components, such as proteins or 
cell membranes. The amount of fluorescence is proportional to the amount of fluorescent probe 
that is bound to a specific cell or component.[64] 
For the work of this thesis, the Flow Cytometer that was used was an Attune Acoustic 
Focusing Cytometer (Applied Biosystems) which is constituted by two lasers: a blue laser (488 
nm) and a red laser (638 nm). These two lasers allow the use and detection of up to six different 
fluorescences: four detected by the blue laser (BL1: green, BL2: orange, BL3: red and BL4: red) 
and the other two detected by the red laser (RL1: light red, RL2: dark red). In all experiments 
performed, at least 1x104 events were acquired using the Attune Cytometric Software (version 
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2.1) and all the data analysis was made using FlowJo (version 10) and GraphPad Prism (version 
6).   
 
2.1.1 Screening of HLA-A02 positive donors by flow cytometry 
Since the PEMs used in this experimental setup were assembled exclusively with MHC I 
molecules of the HLA-A02 allele, only CD8+ T cells from HLA-A02 donors were selected. 
T cells used in the different assays were isolated from buffy-coats which are leuco-platelet 
concentrates. Buffy-coats were provided by Instituto Português do Sangue e da Transplantação 
(IPST), and all blood collection, separation of components and ethical procedures were performed 
by this institute. Each buffy-coat contains approximately 60 mL of blood and was obtained from a 
single healthy donor. Also in IPST, donated blood was screened in order to guarantee that the 
donors were healthy. An analytic imuno-serologic and molecular biologic screening for hepatitis 
B and hepatitis C virus, human immunodeficiency virus (HIV1/2), human T-lymphotropic virus 
(HTLV) and Treponema pallidum bacteria, which is syphilis agent, is performed prior to buffy coat 
receival.  
Since all PEMs technology was optimized for cells from HLA-A02 donors, the first step 
performed was the screening of HLA-A02 positive donors by flow cytometry. To test if donors 
were HLA-A02 positive an aliquot of 100 μL of the leuco-platelet concentrate was placed into two 
tubes of 2 mL (100 μL in each tube) to perform a red blood cell lysis step at the same time that 
cells were stained for flow cytometry. In one of the tubes, 3 μL of PE Mouse anti-human HLA-A02 
Clone BB7.2 (BD PharmingenTM) was added and mixed thoroughly. The tubes were then 
incubated 30 minutes in the dark at room temperature. After incubation, 2 mL of room temperature 
Red Blood Cells Lysis Buffer 1x (see composition on Appendix I) were added in each tube. Tubes 
were pulsed in vortex and incubated at room temperature in the dark for 15 minutes. After lysis, 
the tubes were centrifuged at 500 x g for 5 minutes at room temperature. The supernatant was 
decanted and cells resuspended in 2 mL of phosphate buffered saline (PBS) (see composition 
on Appendix I) and centrifuged again at 500 x g for 5 minutes at room temperature. Finally, the 
supernatant was decanted and cell pellet resuspended in PBS. The samples were then analyzed 
by flow cytometry. An unstained control was used in parallel. The strategy used to analyze if 
donors were HLA-A02 positive is demonstrated in the Figure 2.1. 
 
 
 
 
 
 
 
 
 
17 
 
Figure 2.1 - Strategy used to analyze if the donors tested were HLA-A02 positive or not. After 
flow cytometry acquisitions, a histogram graph of fluorescence channel vs count was generated and if the 
peak of the cells (red) was equal to the peak of unstained cells (blue) the donor was HLA-A02 negative, as 
shown on the right side. Otherwise, if the peak (red) was displaced relatively to the peak of unstained cells 
(blue) the donor was HLA-A02 positive, as shown on the left side. 
 
2.2 Isolation of human peripheral blood mononuclear cells from 
buffy coats by density gradient  
In order to isolate CD8+ T cells from buffy-coats of HLA-A02 positive individuals, peripheral 
blood mononuclear cells (PBMCs) were separated from the other components, namely 
erythrocytes, granulocytes and blood plasma. The separation of the different components was 
made by density gradient centrifugation using Biocoll (Biochrom AG) separation solution (with 
density of 1.077g/mL), which is denser than the lymphocytes and monocytes and less dense than 
the erythrocytes and granulocytes. 
The Biocoll separation solution was pre-warmed at room temperature and added to two 50 
mL tubes (12,5 mL/tube). Then, 25 mL of the buffy coat was slowly added to each tube in order 
to not disturb the Biocoll gradient. The tubes were centrifuged at 1300 x g, for 30 minutes, at room 
temperature, without braking. After centrifugation, the mononuclear cells rings were collected and 
added to a new tube of 50 mL and resuspended with PBS until 50 mL. The samples were 
centrifuged at 900 x g, for 10 minutes at room temperature for platelet removal. The supernatant 
was removed and the pellet was resuspended in PBS. Then PBS was added until 50 mL and a 
sample of PBMCs was collected for counting using a Neubauer chamber. The sample was 
centrifuged again at 900 x g, for 10 minutes at room temperature. After this, a purified fraction 
consisting of PBMCs was obtained for isolation of CD8+ T cells.  
 
2.3 Immunomagnetic isolation of CD8+ T cells from human 
peripheral blood mononuclear cells 
CD8+ T cells were separated from PBMCs, which were previously isolated from buffy coats. 
To isolate CD8+ T cells, PBMCs were resuspended in 80 µL per each 107 cells of cold Beads 
Buffer (see composition on Appendix I) and in 20 µL of human CD8 magnetic microbeads per 
each 30x106 cells. After this step, the cell suspension was incubated at 4ºC for 15 to 30 minutes. 
Then, 2 mL of cold beads buffer was added per each 107 cells and this cell suspension was 
centrifuged for 10 minutes at 300 x g. After centrifugation, the pellet was resuspended in 500 µL 
of cold beads buffer per each 107 cells and the suspension was filtered using a BD Falcon cell 
strainer (100 µm) in order to remove aggregates. Cell suspension was then added to a Miltenyi 
Biotec magnetic separation LS column previously prepared, placed in a support with a magnetic 
field (MidiMACS Separator (Miltenyi Biotec)) and washed with 3 mL of cold beads buffer. Inside 
the column, due to the magnetic field, the CD8+ fraction (labeled cells) stay immobilized in the 
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column while CD8- fraction (unlabeled cells) were eluted from the column to a 15 mL tube. Then, 
a wash step is performed by rinsing the column three times using 3 mL of cold beads buffer. In 
the end, to collect the CD8+ fraction, the column was removed from the magnetic field, 5 mL of 
cold beads buffer was added and the cells were eluted to a 15 mL tube inserting the plunger into 
the column. In order to count the cells in the Neubauer chamber, a sample of each fraction was 
collected. The samples were then centrifuged for 10 minutes at 400 x g. CD8+ T cells were then 
cultured as described in the next section.  
 
2.4 Culture of CD8+ T cells  
CD8+ T cells were cultured in T-75 flasks (Sarstedt) using Roswell Park Memorial Institute 
(RPMI)-1640 medium (Gibco) supplemented with 10% (v/v) of Fetal bovine serum (FBS) (Gibco), 
2mM L-glutamine (Gibco), 100U/mL of penicillin (Gibco), 100 μg/mL of streptomycin (Gibco), 1mM 
sodium pyruvate (Gibco) and 1% (v/v) MEM non-essential amino acids (Gibco). Cells were 
maintained in culture until they were not needed for any assays. Medium was changed every 4-6 
days.  
 
2.5 Efficacy of isolation method  
After isolating CD8+ cells from the buffy coats, the efficacy of the method used for isolation 
was tested by flow cytometry. An aliquot of isolated cells was centrifuged at 400 x g for 5 minutes 
and after supernatant discard the pellet was resuspended in 400 μL of PBS. Cell suspension was 
distributed on 4 tubes (100 μL in each tube). Cells were stained using anti-CD3 Allophycocyanin 
(APC) Clone MEM-57 (ImmunoTools) and anti-CD8 Peridinin chlorophyll protein complex (PerCp) 
Clone UCHT-4 (ImmunoTools). Unstained controls were performed in parallel. After these steps, 
the tubes were incubated for 15 minutes, at room temperature in the dark. Cells were washed 
and centrifuged at 400 x g for 5 minutes and the supernatant discarded. Cells were then 
resuspended in 1 mL of PBS and analyzed by flow cytometry.  
The tubes with unstained cells, cells marked with anti-CD3 APC alone and cells marked with 
anti-CD8 PerCp alone were used for compensation purposes. The percentage of CD8+ T 
lymphocytes isolated from the buffy coat could then be determined. To do this analysis, it is 
important to quantify the cells that were marked with the two antibodies which were the CD8+ 
cells. Double marked cells appear in the quadrant Q2 (Figure 2.2).  
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Figure 2.2 - Gating strategy to evaluate the efficacy of gradient density isolation method. Cells 
isolated were marked with anti-CD3 APC and anti-CD8 PerCp. Double marked cells correspond to CD8+ T 
cells in Q2 quadrant 
 
2.6 Assembly of PEMs 
PEMs, as mentioned before, were synthetized by our collaborators at Jacob’s University 
Bremen. Besides PEMs, which are coated with streptavidin, also biotinylated HLA-A02 molecules 
were synthetized there. Our collaborators produced three types of biotinylated HLA-A02 
molecules: HLA-A02 molecules empty (without any peptide); HLA-A02 molecules complexed with 
a peptide of cytomegalovirus (CMV) and HLA-A02 molecules complexed with a peptide of human 
immunodeficiency virus (HIV). The peptide of CMV is designed NV9 (sequence NLVPMVATV) 
and it is the peptide of interest for providing T cell stimulation. The peptide of HIV is designed IV9 
(sequence ILKEPVHGV) and corresponds to an irrelevant peptide control in the experiments.  
Firstly, aAPCs are required to be assembled. This is achieved by joining streptavidin-coated 
PEMs to biotinylated HLA-A02 molecules, promoting a streptavidin-biotin reaction. This reaction 
is performed by incubating the PEMs with HLA-A02 molecules at 4ºC for 30 minutes. Following 
our collaborators advice, approximatly 200000 capsules would bind 1 ng of HLA protein and all 
experiments were made with this guidance. 
 
2.7 Co-culture of CD8+ T cells with PEMs 
After conjugating PEMs with HLA-A02 molecules, these complexes were incubated with 
cultured CD8+ T cells isolated from healthy donors as described above. A microcapsule to cell 
ratio of 1:1 was used for all experiments. Co-cultures were maintained in RPMI complete medium 
with 10% FBS for up to 72 hours. Co-cultures were made in a 96-well plate round bottom for six 
conditions. Replicates were performed for each condition. 50000 CD8+ T cells were seeded in 
each well. CD8+ T cells alone were used as negative control. Phorbol 12-myristate 13-acetate 
(PMA) and Ionomycin (Ion) were used as positive controls to stimulate and activate CD8+ T cells.  
Experimental conditions included: (1) empty PEMs without HLA-A2 molecules; (2) PEMs 
complexed with empty HLA-A02 molecules; (3) PEMs complexed with NV9-HLA-A02 molecules 
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and (4) PEMs complexed with IV9-HLA-A02 molecules. Table 2.1 resume all conditions tested in 
duplicate for each donor.  
 
Table 2.1 – Conditions tested in the experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.8 Real time PCR 
Real time polymerase chain reaction (real time PCR), also known as quantitative PCR 
(qPCR) is a powerful and sensitive technology for gene expression analysis. In traditional 
polymerase chain reaction (PCR), deoxyribonucleic acid (DNA) or complementary 
deoxyribonucleic acid (cDNA) are used as templates to amplify specific sequences. In this case, 
detection and quantification can only be made in the end of the reaction and analysis usually 
involves gel electrophoresis and imaging analysis. However, in qPCR, quantification is made at 
each cycle since with this technique it is possible to control reactions at exponential amplification. 
For quantification, fluorescent dyes are used and fluorescent signals increase proportionally to 
the number of PCR product molecules making possible the determination of initial concentration 
of DNA or ribonucleic acid (RNA). There are different types of fluorescent dyes that can be used: 
double-strand DNA, PCR primers or probes linked to fluorescent dyes. The data collected from 
the exponential phase of real time PCR is used for quantification and in this phase the instrument 
calculates the threshold and threshold cycle (Ct). Ct is essential for absolute or relative 
quantification and corresponds to the number of the cycle in which the threshold was reached.[66] 
Reactions of real time PCR are usually run for 40 cycles and in each cycle there are three 
principal steps. The first step corresponds to denaturation, where double-stranded DNA is melted 
due to the increase of temperature and single-stranded DNA is formed. The second step is named 
annealing and here an optimal temperature is used to promote the hybridizing of complementary 
sequences to the single stranded DNA formed in the first step. The last step is elongation, 
consisting on primer extension. In this step, the temperature is set around 72ºC, which is the 
optimal temperature for the DNA polymerase activity.[67] 
In the work developed in this thesis, a two-step qRT-PCR was performed. It consists of using 
a reverse transcriptase enzyme to perform a reverse transcription of total RNA into cDNA. After 
this step, part of cDNA is placed in the tube where real-time PCR reaction will take place. 
Conditions Tested (in duplicate for each donor) 
CD8+ T cells 
CD8+ T cells + PMA + Ion 
CD8+ T cells + PEMs 
CD8+ T cells + PEMs + HLA-A02 empty 
CD8+ T cells + PEMs + HLA-A02 + NV9 
CD8+ T cells + PEMs + HLA-A02 + IV9 
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Regarding detection chemistry, there are two types that have been developed: TaqMan 
chemistry and SYBR Green I dye chemistry. In the context of this thesis, TaqMan was used, 
which is also known as fluorogenic 5’ nuclease chemistry. This chemistry is based on two 
phenomena: the first is the capacity that 5’ nuclease domain has to break down, downstream of 
DNA synthesis, the DNA that is bound to template and the second is the fluorescence resonance 
energy transfer (FRET) phenomenon. In this phenomenon, fluorescent emissions of one dye 
(reporter) are suppressed by the nearest presence of another dye (quencher). So, in TaqMan 
chemistry, exclusive TaqMan probes are used. Probes are constituted by a reporter, bound to the 
5’ end, and a quencher, bound to the 3’ end, that allows the FRET phenomenon to occur, since 
they have affinity to each other. In the beginning of the reaction the probe is intact, these are the 
reporter and the quencher that are near each other because their affinity and the FRET 
phenomenon is occurring. When PCR reaction begins, both primers and probe anneal to the 
target sequence of the template. DNA polymerase start their activity and extend the primer. When 
DNA polymerase achieves the probe cleaves it with her 5’ nuclease activity. The cleavage 
separates the quencher from the reporter and its fluorescence is restored. During the process 
many probes are cleavaged and the fluorescent intensity starts to increase proportionally to the 
amount of amplicon formed [68]. In order to quantify the relative gene expression using the data 
collected by real-time PCR experiments, the 2-ΔΔCt method, developed by Livak and Schmittgen 
[69], also known as comparative threshold method was used. With this method, it is possible to 
calculate the relative expression of a target gene relatively to a reference control. Reference 
control is given by the expression of an endogenous housekeeping gene. An ideal housekeeping 
gene is a gene that presents a constant expression independently of experimental conditions, 
such as the tissue analyzed, cell type and stage of development. Two of the most common genes 
used as control genes and the ones that were used in the experiments of this thesis are ACTB 
gene, that codes -actin (a cytoskeletal protein), and GADPH which encodes for glyceraldehyde-
3-phosphate dehydrogenase, a glycolytic enzyme. Using the mathematical method mentioned 
before, it was possible to calculate the amount of target gene in the sample. This amount 
normalized to endogenous control and relative to the normalized calibrator is given by 2-ΔΔCt, 
where Ct indicates the cycle number in which the fluorescent signal reaches the threshold; ΔCt 
indicates the variation between the Ct of the target gene and the Ct of the housekeeping gene 
and ΔΔCt corresponds to the variation of ΔCt of the sample of interest and the ΔCt of the calibrator 
[69], [70].  
 
2.8.1 Analysis of genetic expression of IFN-γ in the cells recovery from co-
cultures experiments, by RT-PCR 
Reverse transcriptase polymerase chain reaction (RT-PCR) protocol was performed to 
analyze the genetic expression of IFN-γ in the cells recovered from the co-cultures. Total RNA 
was extracted from T cells using the GenEluateTM Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich)[71]. All steps were carried at 4ºC. Cells were lysed using the lysis buffer (1% of 2-
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Mercaptoethanol (Sigma) per 1 mL of lysis solution. Approximately 5 x 106 cells were used per 
lysis. Total cell lysates were passed into a filtration column and centrifuge at 12000 x g, for 2 
minutes. The filtration column was then discarded and 250 μL of 70% of ethanol was added to 
the filtered lysate, pipetting thoroughly. The lysate/ethanol mixture was placed into a binding 
column for RNA retrieval and centrifuged at 1200 x g for 2 minutes. The flow-through liquid was 
discarded. 250 μL of wash solution 1 was added to the column and centrifuged at 1200 x g for 2 
minutes. The flow-through liquid was discarded and the DNA digestion was performed. For this, 
DNase I (Sigma) was prepared mixing 10 μL of DNase I with 70 μL of digest buffer by inversion. 
The 80 μL of the mixture prepared was added directly onto the filter in the binding column and the 
tubes were incubated for 15 minutes at room temperature. After incubation period, 250 μL of wash 
solution 1 was added into the column and centrifuge at 1200 x g for 2 minutes. The flow-through 
liquid was discarded and 500 μL of wash solution 2 was pipetted into the column, centrifuged at 
1200 x g for 2 minutes and the flow-through liquid discarded again. A second 500 μL of wash 
solution 2 was added into the column, centrifuged at 1200 x g for 2 minutes and the flow-through 
liquid discarded. After that another centrifugation at 1200 x g for 2 minutes was performed and 
then the binding column was placed into a fresh 2 mL collection tube. In order to elute the RNA, 
55 μL of elution solution was added into the binding column and centrifuged at 1200 x g for 2 
minutes. The flow-through liquid was pipetted again to the column and centrifuged at 1200 x g for 
2 minutes. At this point the purified RNA was recovered from the flow-through liquid.  
The second step of RT-PCR protocol was conversion of RNA to cDNA, which was performed 
using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). In this conversion 
it was used random primers which can hybridize with several regions of RNA allowed transcription 
by reverse transcriptase enzyme. To do the conversion, 50 μL of the purified extracted RNA and 
50 μL of the conversion mix were added to a PCR tube. The content of conversion mix and 
respective amounts are described in the following table. 
 
Table 2.2 – Components of conversion mix and respective amounts (μL) 
Components Amounts (μL) 
Buffer (10x) 10 
Random primers (10x) 10 
dNTP’s (100 mM) 4 
Reverse transcriptase enzyme 5 
RNase free H2O 21 
 
The cDNA synthesis was then performed on a Programmable Thermal Controller PTC-100TM 
(MJ Research, Inc.) thermocycler according to the program mentioned in the table. After 
conversion the samples were stored at -20ºC until real-time PCR was performed. 
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Table 2.3 – Settings of the used program to cDNA conversion 
 Step 1 Step 2 Step 3 Step 4 
Temperature (ºC) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
 
 
 For RT-PCR experiments, the samples were prepared in RT-PCR tubes (Simport) to a 
final volume of 10 μL. Each sample was prepared in duplicate and adding 2 μL of 1:4 diluted 
probe, 2 μL of cDNA, 1 μL of RNase free H2O and 5 μL of TaqMan Fast Universal PCR Master 
Mix 2x (Applied Biosystems) per tube. The probe of interest was IFN-γ (Hs00174143_m1, Applied 
Biosystems) and the endogenous control were GADPH (Hs03929097_g1, Applied Biosystems) 
and β-actin (Hs99999903_m1, Applied Biosystems). Reactions were run on a Rotor-Gene 6000 
Sereies (Corbett) according to table 2.4. 
 
Table 2.4 – Settings of the used program to RT-PCR assay  
 Step 1 (1 cycle) Step 2 (40-50 cycles) 
Temperature (ºC) 95 95 60 
Time (seconds) 20 3 30 
 
  
CT was determined by using Rotor-Gene 6000 Sereis software (version 1.7). Relative 
messenger ribonucleic acid (mRNA) levels were calculated with 2-ΔCT x 1000 equation and 
normalized against arithmetic means of the expression of the endogenous genes (GADPH and 
β-actin). The equation allows the calculation of mRNA molecules of each gene of interest per 
1000 molecules of endogenous controls. Results were analyzed using Microsoft Office Excel and 
GraphPad Prism (version 6).  
 
2.9 Enzyme-Linked Immunosorbent Assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) is a colorimetric technique that allows 
qualitative or quantitative determinations of antigens or antibodies and it is based on the concept 
that an antigen binds to its specific antibody. ELISA is used as a diagnostic tool and also in 
biomedical research [72]. With this assay, it is possible to detect small amounts of antigens 
(proteins, peptides, hormones) or antibodies in a fluid sample. Typically, the first step of ELISA 
consists on the immobilization of an antigen on wells of a 96 well microplate. After that, test 
antibodies specific for the antigen are added followed by the addition of secondary antibodies 
conjugated with enzyme which are against test antibodies. Last step consists of the addition of a 
chromogenic substrate for the enzyme which will give color, fluorescent or luminescent products 
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that allows determination of reagents concentrations. Colorimetric reading provides quantitative 
or qualitative measures. Most commonly used enzymes in ELISA are horseradish peroxidase 
(HRP) and alkaline phosphatase (ALP) and the most commonly used chromogenic substrate is 
3,3',5,5'-tetramethylbenzidine (TMB). There are various types of ELISAs due to variations that are 
made to the procedure. In this thesis it was used a variant called capture ELISA. This type of 
ELISA is used to detect a specific antigen in a sample and for that a capture antibody specific for 
the antigen is immobilized on the plate. After that the sample containing the antigen of interest is 
added to each well and the specific antigen will bind to the immobilized antibody. At last, another 
antibody specific for the antigen is added (the binding antibody). This latter antibody allows 
detection of the antigen after the HRP enzyme and the chromogenic substrate is added [73]–[75]. 
In the ELISA’s performed for the work of this thesis, a biotin-streptavidin system was used, 
since the binding antibody used is biotinylated and HRP enzyme is conjugated with streptavidin 
which amplifies the signal since the amount of enzyme bound is increased. TMB was used as 
chromogenic substrate. When HRP enzyme reacts with TMB, a blue color appears. After the 
addition of an acidic solution, blue color turns yellow that can be detected on a spectrophotometer 
plate reader at 450 nm wavelength. SpectraMax 190 Microplate Reder (Molecular Devices) and 
SoftMax Pro were used to read the plates and collect the data, respectively. Collected data were 
analyzed using Microsoft Office Excel and GraphPad Prim 6. 
 
2.9.1 Capture ELISA for assessment of IFN-γ in co-culture supernatants 
In order to do a absolute quantification of IFN-γ in co-cultures supernatants, an ELISA kit 
(Immunotools) was used following manufacturer’s instructions. To do ELISA technique, the wells 
of a high binding 96-well plate (Costar) were coated with 50 μL of capture antibody diluted 1:100 
in PBS for ELISA. The plate was incubated at 4ºC, overnight. After incubation period, the captured 
antibody was removed and 200 μL of blocking buffer (see compositon on Appendix I) was added 
to each well. At this point, the plate was incubated for 1 hour at room temperature. To do a 
standard curve, the standards were prepared with a serial dilution of 1:2 from 4000 pg/mL to 0 
pg/mL. To do the dilutions it was used blocking buffer. After 1 hour incubation, the blocking buffer 
was removed. 50 μL of each standard and each sample were added, in duplicate, in their 
respective wells. The plate was then incubated for 2 hours at room temperature. Afterwards, the 
plate was washed five times with 200 μL of washing buffer (see composition on Appendix I) for 
each well at each time. Biotinylated antibody was diluted 1:100 in blocking buffer, 50 μL of this 
antibody was added to each well and the plate was incubated 2 hours at room temperature. Plate 
was again washed five times with 200 μL of washing buffer for each well and 50 μL of Poly-HRP-
Streptavidin-HS enzyme previously diluted 1:1000 were added to each well. After 30 minutes 
incubation at room temperature, the plate was washed again with the same conditions and 50 μL 
of TMB substrate was added at each well. The plate was incubated in the dark at room 
temperature until optical color development. Finally, the reaction was stopped by addition of 25 
μL of 4M HCl and the optical density was read at 450 nm.  
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2.10 Experiment to test the link between PEMs and CD8+ cells 
In order to test if PEMs can bind to CD8+ cells, these two were co-cultured for 24 hours in 
BD Falcon Conical Tubes and the results were analyzed by flow cytometry.  
Experimental conditions included the co-culture of CD8+ T cells with: (1) PEMs; (2) PEMs 
containing empty HLA-A02 molecules; (3) PEMs containing NV9-HLA-A02 molecules and (4) 
PEMs containing IV9-HLA-A02 molecules. Unstimulated CD8+ T cells were used as control. 
For flow cytometry analysis, after PEMs preparation (as described in section 2.6), 
biotinylated fluorescein isothiocyanate (FITC) was added in each tube in order to compete with 
the biotinylated HLA-A02 molecules for the streptavidin binding site. After assembly, PEMs were 
cultured with CD8+ cells using the different conditions for 24 hours. At the defined time point, cells 
were stained with an anti-CD8 phycoerythrin (PE)-conjugated antibody. Samples were analyzed 
by flow cytometry, using a proper gating strategy.  
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3 Results and Discussion 
 
The work developed for this thesis had as main objective to test the capacity of PEMs to 
activate T cells. These aAPCs were synthesized with the aim of mimicking the role that dendritic 
cells have in vivo. Previously, PEMs were tested using murine lymphocytes, and the activation or 
response was measured by the secretion of IFN-γ. The assays developed within this thesis aimed 
to test the PEMs ability to activate human lymphocytes.  
 
3.1 Screening of HLA-A02 positive donors  
 Since all of PEMs technology was developed for HLA-A02 positive cells, the first step was 
to isolate CD8+ T cells from HLA-A02 donors. For this purpose, the buffy coats provided by IPST 
were tested in order to find HLA-A02 positive donors. These tests were done by flow cytometry 
as described above. The graphs below (Figure 3.1) correspond to the results of the buffy coats 
tested. The strategy used to analyze the results is described in section 2.1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 - Screening of HLA-A02 donor by flow cytometry. On the histograms the yy axis 
represent the number of events and the xx axis represents the fluorescence intensity on the BL2 channel. 
In blue are represented the unstained cells and in red the cells stained with HLA-A02 PE. A – Two 
histogramss (blue and red) are overlapped, representing a HLA-A02 negative donor. B,C,D,E,F,G,H,I – The 
two histograms that are not overlapped being the red peak (stained cells) moved to the right. These represent 
HLA-A02 positive donors.  
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The Figure 3.1A corresponds to a HLA-A02 negative donor, since the two histograms (blue 
- unstained cells; and red - marked cells) are overlapping, and all other graphs (Figures 3.1B to 
3.1I) correspond to HLA-A02 positive donors. There were many other HLA-A02 negative donors 
that were tested but since the buffy coats from that donors were not used those results were 
omitted. In total 40 buffy coats were tested, being 70% from male donors and 30% from female 
donors. The buffy coats were from donors with age between 18 and 65 years.  The cells isolated 
from the buffy coat of donor A were used as a negative control.  
After testing whether the donors were HLA-A02 positive or not, CD8+ T cells were isolated 
by the density gradient method previously described. 
 
3.2 Efficacy of CD8+ T cells isolation 
In order to check the effectiveness of the isolation of CD8+ cells from buffy coats, flow 
cytometry was used to see if cells isolated were in fact CD8+ T cells. In this analysis, antibodies 
recognizing specific surface markers of CD8+ cells, such as CD3 and CD8, were used. The 
protocol analysis strategy used were described in section 2.5.  
This analysis was only done on cells isolated from the first six donors to prove the 
effectiveness of the method used for isolation.   
Figure 3.2 - Percentage of CD8+ T cells isolated from each from donors A,B,C,D,E and F. CD8+ 
T cells appear on Q2 quadrant since cells isolated were stained with two markers (CD3 APC and CD8 
PerCp) to distinguish CD8+ T cells. On Q2 quadrant appear the double stained cells, so the CD8+ T cells. A 
– Cells isolated from donor A, being 94.9% of the cells isolated CD8+ T cells. B – Cells isolated from donor 
B, being 86.3% of the cells CD8+ T cells. C – Cells isolated from donor C. 84.8% of isolated cells were CD8+ 
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T cells. D – Cells isolated from donor D. 90.5% were CD8+ T cells. E – Cells isolated from donor E, being 
93.6% of the cells CD8+ T cells. F - Cell– isolated from donor F. 87.9% of the cells isolated were CD8+ T 
cells. 
 
The results obtained by flow cytometry to verify the efficacy of isolation method are detailed 
in Figure 3.2. An aliquot of cells from isolation was marked with two different antibodies that are 
specific for CD8+ cells. In the experiments, the antibodies used were anti-CD3 allophycocyanin 
(APC) conjugated, which is specific for lymphocytes, and anti-CD8 peridinin-chlorophyll-protein 
(PerCp), which is specific for CD8+ cells. Through analysis of the results obtained, it is possible 
to verify that the majority of the cells that were isolated are CD8+ T cells. Since CD8+ T cells are 
stained using two antibodies, these cells appear in Q2 quadrant of the graphs presented in Figure 
3.2. Figure 3.2A shows an efficacy of 94.4%, since 94.4% of the cells that were isolated were 
CD8+ cells. The isolation of CD8+ cells from donor B (Figure 3.2B) led to an efficacy of 86.3% and 
from donor C (Figure 3.2C) of 84.6%. Figure 3.2D proves that from donor D 90.5% the cells 
isolated were CD8+ cells and Figure 3.2E shows that 93.6% of the cells isolated from donor E 
were CD8+ cells. Finally, we can also see that from donor F 87.9% (Figure 3.2F) of the cells that 
were isolated from the buffy coat, there were the interested cells – CD8+ cells.  
All these results permit to conclude that the method of the density gradient followed by 
immunomagnetic separation for isolating CD8+ cells from the buffy coats was successful since 
the purity of CD8+ cells isolated for each donor was on average above > 89.7% ± 3,7%. 
 
3.3 Analysis of 24 hours genetic expression of IFN-γ by T cells  
Firstly, co-cultures of PEMs with CD8+ cells were maintained for 24 hours. After this period, 
the supernatant and the cells were collected. The cells were lysed and the ribonucleic acid (RNA) 
was extracted, further converted into complementary deoxyribonucleic acid (cDNA) and the 
expression of IFN-γ was studied by quantitative polymerase chain reaction (qPCR). Figure 3.3 
presents the results that were obtained. 
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Figure 3.3 - Genetic expression of IFN-γ measured by RT-PCR in the cells recovered from co-
cultures experiments at 24 hours. In the graphs, it is shown the relative mRNA expression of IFN-γ gene. 
The yy axis represents the relative mRNA levels and the xx axis represents the different conditions studied. 
CD8 – CD8+ T cells were cultured alone. CD8+PMA+ION – CD8+ T cells were stimulated with PMA and 
Ionomycin (positive control). CD8+PEMs – CD8+ T cells were co-cultured with PEMs (microcapsules). 
CD8+PEMs+HLA – CD8+ T cells were put in culture with PEMs linked to HLA-A02 molecules without any 
peptide. CD8+PEMs+HLA+NV9 – CD8+ T cells were co-cultured with PEMs linked to HLA-A02 molecules 
complexed with NV9 peptide (CMV peptide). CD8+PEMs+HLA+IV9 – CD8+ T cells were cultured with PEMs 
linked to HLA-A02 molecules complexed with the IV9 peptide (HIV peptide – irrelevant control). A - Relative 
mRNA expression of IFN-γ of donor A. B - Relative mRNA expression of IFN-γ of donor B. C - Relative 
mRNA expression of IFN-γ of donor C. D - Relative mRNA expression of IFN-γ of donor D.    
 
In all donors (A, B, C and D) it is possible to verify that positive controls worked (Figure 3.3 
second column of all graphs), because there was a great increase of IFN-γ expression when the 
cells were put in culture in the presence of Phorbol 12-myristate 13-acetate (PMA) and Ionomycin 
(Ion). 
In donor A (Figure 3.3A) there was expression of IFN-γ only in positive control. This was 
expected since donor A was HLA-A02 negative and all the PEMs technology was optimized for 
HLA-A02 positive donors.  
In donor B (Figure 3.3B) there was a very small increase of the expression of IFN-γ when 
the CD8+ cells were cultured with the presence of the PEMs (third column) and when the cells 
were co-cultured with PEMs with HLA-A02 complexed with the NV9 peptide (fifth column). Donor 
C (Figure 3.3C) presented a great increase of the IFN-γ expression when the cells where cultured 
with PEMs with HLA-A02 complexed with NV9 and donor D (Figure 3.3D) only expressed IFN-γ 
in positive control.  
 Since donors B, C and D were HLA-A02 positive, an increase of the expression of IFN-γ 
when the CD8+ cells were cultured with PEMs with HLA-A02 molecules complexed with the NV9 
peptide was expected. This fact only happened with significance in donor C probably because it 
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was the only CMV positive donor. Since the donors were not tested for CMV, it was not possible 
to know in advance if the donors were responsive or not to the CMV peptide. 
In four donors non-stimulated cells (CD8+ cells alone) didn’t express IFN-γ. As positive 
control, PMA+Ion stimulated cells expressed 899.0 ± 661.9 copies of IFN-γ. Cells stimulated with 
PEMs alone expressed 10.64 ± 8.9 copies of IFN-γ and cells stimulated with PEMs complexed 
with HLA-A02 molecules expressed 2.5 ± 2.5 copies. CD8+ cells stimulated with PEMs complexed 
with NV9-HLA-A02 molecules expressed 516.8 ± 513.1 copies and the cells stimulated with PEMs 
complexed with IV9-HLA-A02 molecules expressed 0.03 ± 0.03 copies of IFN-γ. 
 
3.4 Analysis of 24 hours expression of IFN-γ protein by T cells 
To confirm the results that were obtained with qPCR, an Enzyme-Linked Immunosorbent 
Assay (ELISA) technique was performed. For ELISA there were used the supernatants collected 
from the co-culture after 24 hours. The results obtained by ELISA are shown in Figure 3.4. 
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Figure 3.4 – Expression of IFN-γ measured by ELISA in the supernatants recovered from co-
cultures experiments at 24 hours. In the graphs it is shown the concentration (pg/mL) of IFN-γ. The yy 
axis represents the concentration in pg/mL of IFN-γ in the supernatants and the xx axis represents the 
different conditions studied. CD8 – CD8+ T cells were cultured alone. CD8+PMA+ION – CD8+ T cells were 
stimulated with PMA and Ionomycin (positive control). CD8+PEMs – CD8+ T cells were co-cultured with 
PEMs (microcapsules). CD8+PEMs+HLA – CD8+ T cells were put in culture with PEMs linked to HLA-A02 
molecules without any peptide. CD8+PEMs+HLA+NV9 – CD8+ T cells were co-cultured with PEMs linked to 
HLA-A02 molecules complexed with NV9 peptide (CMV peptide). CD8+PEMs+HLA+IV9 – CD8+ T cells were 
cultured with PEMs linked to HLA-A02 molecules complexed with the IV9 peptide (HIV peptide – irrelevant 
control). A – Concentration of IFN-γ on supernatants from donor A. B - Concentration of IFN-γ on 
supernatants from donor B. C - Concentration of IFN-γ on supernatants from donor C. D - Concentration of 
IFN-γ on supernatants from donor D.  
 
The results obtained show an increase of the secretion of IFN-γ in positive controls (second 
column) in all donors (Figure 3.4A, B, C and D). It is also clear a tendency of positive expression 
in all other conditions in all donors but it is not possible to see a bigger expression when the cells 
were cultured with the presence of PEMs with HLA-A02 complexed with NV9 even in donor C 
where it was expected to be seen.  
Non-stimulated cells expressed 24.5 ± 12.5 pg/mL of IFN-γ. Positive controls, cells stimulated 
with PMA+Ion, expressed 1413 ± 686.6 pg/mL of IFN-γ and cells stimulated with PEMs expressed 
45.6 ± 1.7 pg/mL of IFN-γ. Cells that were stimulated with PEMs complexed with HLA-A02 
molecules expressed 42.1 ± 3.9 pg/mL of IFN-γ. CD8+ cells stimulated with PEMs complexed 
with NV9-HLA-A02 molecules expressed 62.8 ± 8.0 pg/mL of IFN-γ and cells stimulated with 
PEMs complexed with IV9-HLA-A02 molecules expressed 36.4 ± 2.1 pg/mL of IFN-γ.  
With these results, it was hypothesized that probably cells need to be stimulated for longer 
periods of time with PEMs, so that these ones can activate them via signal 1 and the cells produce 
and release the sufficient amounts of IFN-γ to be detected in supernatants by ELISA. For this 
reason the co-culture time was increased to 72 hours.  
  
3.5 Analysis of 72 hours genetic expression of IFN-γ by T cells  
As mentioned before the time of co-cultures was increased to 72 hours being all the 
procedures maintained. So, after 72 hours of co-culture, the supernatant was collected and the 
cells lysed and the RNA extracted. After conversion of the RNA for cDNA the genetic expression 
was analyzed by qPCR. The results obtained are in Figure 3.5. 
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Figure 3.5 - Genetic expression of IFN-γ measured by RT-PCR in the cells recovered from co-
cultures experiments at 72 hours. In the graphs it is shown the relative mRNA expression of IFN-γ gene. 
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The yy axis represents the relative mRNA levels and the xx axis represents the different conditions studied. 
CD8 – CD8+ T cells were cultured alone. CD8+PMA+ION – CD8+ T cells were stimulated with PMA and 
Ionomycin (positive control). CD8+PEMs – CD8+ T cells were co-cultured with PEMs (microcapsules). 
CD8+PEMs+HLA – CD8+ T cells were put in culture with PEMs linked to HLA-A02 molecules without any 
peptide. CD8+PEMs+HLA+NV9 – CD8+ T cells were co-cultured with PEMs linked to HLA-A02 molecules 
complexed with NV9 peptide (CMV peptide). CD8+PEMs+HLA+IV9 – CD8+ T cells were cultured with PEMs 
linked to HLA-A02 molecules complexed with the IV9 peptide (HIV peptide – irrelevant control). A - Relative 
mRNA expression of IFN-γ of donor E. B - Relative mRNA expression of IFN-γ of donor F. C - Relative mRNA 
expression of IFN-γ of donor G. D - Relative mRNA expression of IFN-γ of donor H. E - Relative mRNA 
expression of IFN-γ of donor I.  
 
Analyzing the results obtained by qPCR, it is possible to confirm that the positive controls 
(second column of all graphs – Figure 3.5) are reproducible, since there was an increase of the 
expression of IFN-γ in all donors (E, F, G, H and I) when the cells were stimulated with PMA and 
Ion. 
In donor E (Figure 3.5A) there wasn’t any expression in other conditions than positive control. 
This could be due to the fact that the donor wasn’t CMV positive like it was mentioned before.  
Donor F (Figure 3.5B) and donor H (Figure 3.5D) present a small increase (less than 20 
copies) of the expression of IFN-γ in the other conditions that are not significant when compared 
to the expression in the positive control.  
Donor G (Figure 3.5C), besides positive control, shows increased expression of IFN-γ when 
the cells where co-cultured with PEMs with HLA-A02 molecules complexed with CMV peptide 
(fifth column). This result could indicate that donor G was CMV-responsive and T cells were 
activated by PEMs technology.  
Donor I (Figure 3.5E), presents a small increase of the IFN-γ expression when cells were co-
cultured with PEMs alone (third column).  
All together these results show that non-stimulated cells expressed 4.2 ± 1.8 copies of IFN-
γ. CD8+ cells stimulated with PMA+Ion expressed 13275 ± 8620 copies of IFN-γ and the ones 
stimulated with PEMs alone expressed 4.4 ± 3.1 copies. Cells that were stimulated with PEMs 
complexed with HLA-A02 molecules expressed 7.2 ± 4.5 copies of IFN-γ and cells stimulated with 
PEMs complexed with NV9-HLA-A02 molecules expressed 22.4 ± 18.2 copies. CD8+ cells 
stimulated with PEMs complexed with IV9-HLA-A02 molecules expressed 5.2 ± 3.7 copies of IFN-
γ. 
Increase of the expression of IFN-γ in other conditions when the CMV peptide is not present, 
can happen because PEMs in culture with the cells can interfere with some activation 
mechanisms (basal activation) and a small expression is noticed. 
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3.6 Analysis of 72 hours expression of IFN-γ protein by T cells 
The qPCR results from previous section were compared to the results obtained using the 
ELISA technique. ELISA results are presented in Figure 3.6. 
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Figure 3.6 - Expression of IFN-γ measured by ELISA in the supernatants recovered from co-
cultures experiments at 72 hours. In the graphs it is shown the concentration (pg/mL) of IFN-γ. The yy 
axis represents the concentration in pg/mL of IFN-γ in the supernatants and the xx axis represents the 
different conditions studied. CD8 – CD8+ T cells were cultured alone. CD8+PMA+ION – CD8+ T cells were 
stimulated with PMA and Ionomycin (positive control). CD8+PEMs – CD8+ T cells were co-cultured with 
PEMs (microcapsules). CD8+PEMs+HLA – CD8+ T cells were put in culture with PEMs linked to HLA-A02 
molecules without any peptide. CD8+PEMs+HLA+NV9 – CD8+ T cells were co-cultured with PEMs linked to 
HLA-A02 molecules complexed with NV9 peptide (CMV peptide). CD8+PEMs+HLA+IV9 – CD8+ T cells were 
cultured with PEMs linked to HLA-A02 molecules complexed with the IV9 peptide (HIV peptide – irrelevant 
control). A – Concentration of IFN-γ on supernatants from donor E. B - Concentration of IFN-γ on 
supernatants from donor F. C - Concentration of IFN-γ on supernatants from donor G. D - Concentration of 
IFN-γ on supernatants from donor H. E - Concentration of IFN-γ on supernatants from donor I. 
 
With these results, it is possible to confirm that positive controls were working, since there 
was increased secretion of IFN-γ when cells were stimulated with PMA and Ion. In donors E and 
F (Figure 3.6A and Figure 3.6B) it was possible to detect reduced levels of IFN-γ produced for all 
other conditions. It may happen because of the sensitivity of the technique. 
In donor G (Figure 3.6C) the results obtained confirm the ones obtained by qPCR, since 
there was a significant expression when the cells were cultured with PEMs with HLA-A02 
complexed with NV9 peptide. Both results (qPCR and ELISA) suggest that donor G was CMV 
positive and PEMs could activate T cells against the peptide that was presented.  
Donor H shows an isolated higher expression when cells were in contact with PEMs alone 
(Figure 3.6D). Once again, this may indicate that PEMs (since they are strange particles to the 
cells) can interfere with some signaling pathways and activation mechanisms.  
In donor I (Figure 3.6E) the results are the same that the ones obtained by qPCR, showing 
a small increase when cells were alone in culture and when they were cultured with PEMs alone.  
Considering the results of the five donors, non-stimulated cells expressed 24.8 ± 7.9 pg/mL 
of IFN-γ and cells stimulated with PMA+Ion, expressed 2215 ± 1033 pg/mL of IFN-γ. CD8+ cells 
stimulated with PEMs expressed 44.3 ± 9.9 pg/mL of IFN-γ and cells that were stimulated with 
PEMs complexed with HLA-A02 molecules expressed 30.6 ± 14 pg/mL of IFN-γ. CD8+ cells 
stimulated with PEMs complexed with NV9-HLA-A02 molecules expressed 135.5 ± 111.4 pg/mL 
of IFN-γ and cells stimulated with PEMs complexed with IV9-HLA-A02 molecules expressed 34.4 
± 12.4 pg/mL of IFN-γ.  
All the results obtained by qPCR and ELISA from all co-cultures suggest that PEMs with 
HLA-A02 molecules complexed with CMV peptide can activate T cells from donors, supposing 
they had previous contact with the CMV virus and therefore have CMV-reactive lymphocytes. It 
also indicates that PEMs are microcapsules that are not very stable and can interfere with some 
signaling mechanisms of the cells inducing unspecific increases of the expression of IFN-γ. 
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3.7 Confirmation of the binding between PEMs and CD8 cells 
 To confirm that PEMs can bind to CD8+ cells, we set up a method that allowed the 
identification of PEMs by flow cytometry. The methodology used to perform these tests is 
described in section 2.10 and to analyze the results obtained, it was used the gate strategy 
illustrated in Figure 3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - Gate strategy used to test the binding between PEMs and CD8 T cells. A – First, there 
were selected only the events stained with anti-CD8 PE. B – From anti-CD8 PE stained events, it was 
selected only the doublets. For this purpose, we performed a FSC-A:FSC-H dot plot and selected the events 
that were not in the diagonal. C-Finally the two fluorescences were intersected and the doublets double 
stained with biotin FITC and anti-CD8 PE correspond to PEMs binding with CD8+ cells.     
 
Firstly, the gating strategy selected the eventsstained with anti-CD8 phycoerythrin (PE) – 
Figure 3.7A. From the anti-CD8 PE stained events, only the doublets that could be PEMs-PEMs, 
PEMs-CD8+ cells or CD8+ cell-CD8+ cells were selected (Figure 3.7B).. The gating selection 
included the doublets that were double stained, that is, stained with both biotin FITC and anti-
CD8 PE (Figure 3.7C). These doublets double stained correspond to the PEMs binding to CD8+ 
cells. 
Controls were first analyzed and the results are shown in Figure 3.8.  
 
A B 
C 
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Figure 3.8 - PEMs in the different conditions stained with biotin FITC and CD8 PE. A1 – PEMs 
stained with biotin FITC (red) and unstained cells (blue). A2 – PEMs stained with CD8 PE (purple) and 
unstained cells (blue). B1 – PEMs with HLA-A02 stained with biotin FITC (red) and unstained cells (blue). 
B2 - PEMs with HLA-A02 stained with CD8 PE (purple) and unstained cells (blue). C1 – PEMs with HLA-
A02 complexed with NV9 peptide stained with biotin FITC (red) and unstained cells (blue). C2 - PEMs with 
HLA-A02 complexed with NV9 peptide stained with CD8 PE (purple) and unstained cells (blue). D1 – PEMs 
A1 A2 
B2 B1 
C2 C1 
D1 D2 
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with HLA-A02 complexed with IV9 peptide stained with biotin FITC (red) and unstained cells (blue). D2 - 
PEMs with HLA-A02 complexed with IV9 peptide stained with CD8 PE (purple) and unstained cells (blue). 
 
Figure 3.8A corresponds to PEMs stained with biotin-FITC and anti-CD8 PE. In Figure 3.8B 
it is shown the results obtained for PEMs with HLA-A02 molecules stained with biotin-FITC and 
anti-CD8 PE. Results from PEMs with HLA-A02 molecules complexed with NV9 peptide and 
PEMs with HLA-A02 molecules complexed with IV9 peptide both stained with biotin FITC and 
anti-CD8 PE are represented in Figures 3.8C and 3.8D respectively.  
These results show that in all the situations tested, PEMs are stained with biotin-FITC 
(Figures 3.8A1, 3.8B1, 3.8C1 and 3.8D1) but not with anti-CD8 PE (Figures 3.8A2, 3.8B2, 3.8C2 
and 3.8D2). All the results obtained were expected, since PEMs are coated with streptavidin, and 
this molecule binds naturally to biotin molecules. Otherwise, PEMs are microcapsules that do not 
have CD8 molecules, that’s why the antibody CD8 PE didn’t bind to the PEMs in any condition. 
With these controls it was possible to guarantee that the biotin FITC binds to PEMs in any 
condition and the antibody CD8 PE didn’t bind to PEMs in any condition.  
After this, it was possible to analyze the binding between PEMs and CD8+ cells after 24 
hours of co-culture. To do these experiments there were used CD8+ cells from three different 
donors and the results are in Figures 3.9, 3.10 and 3.11.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 3.9 – Binding between PEMs and CD8 cells analyzed by flow cytometry. In Q2 quadrant 
are the doublets (PEMs+CD8) double stained with biotin FITC and CD8 PE. CD8+ T cells used in co-culture 
were from donor G. A – Results from co-culture of PEMs (just the microcapsules) and CD8+ cells. B – Results 
from co-culture of PEMs with HLA-A02 with CD8+ cells. C- Results from co-culture of PEMs with HLA-A02 
complexed with NV9 peptide with CD8+ cells. D - Results from co-culture of PEMs with HLA-A02 complexed 
with IV9 peptide with CD8+ cells. 
 
Figure 3.9 shows the results obtained by flow cytometry to confirm that PEMs can bind to 
CD8+ cells. CD8+ cells used in this assay were from a suppose CMV positive donor. The 
percentage of binding when CD8+ cells were co-cultured with PEMs alone was 1.51% (Figure 
3.9A) and when CD8+ cells were co-cultured with PEMs with HLA-A02 molecules was 1.75% 
(Figure 3.9B). Figure 3.9C shows that the percentage of binding was 1.38% when CD8+ cells 
were cultured with PEMs with HLA-A02 molecules complexed with NV9 peptide and Figure 3.9D 
shows the percentage of binding when CD8+ cells were co-cultured with PEMs with HLA-A02 
molecules complexed with IV9 peptide was about 1.31%. 
These results were not expected since it was believed that PEMs should bind preferentially 
when there were HLA-A02 molecules complexed with NV9 peptide in CMV positive donors. 
Analyzing the results it is possible to see a bigger percentage of binding when the cells were co-
cultured with PEMs with HLA-A02 molecules without any peptide (Figure 3.9B). With these 
results, we can conclude that PEMs bind to CD8+ cells irrespectively of the peptide being 
presented, showing no differences in percentage of binding from one condition to another. This 
results suggests that PEMs are not specific since they don’t bind to a higher number of CD8+ cells 
when the NV9 peptide is present.   
 
 
 
 
 
~ 
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Figure 3.10 - Binding between PEMs and CD8 cells analyzed by flow cytometry. In Q2 quadrant 
are the doublets (PEMs+CD8) double stained with biotin FITC and CD8 PE. CD8+ T cells used in co-culture 
were from donor I. A – Results from co-culture of PEMs (just the microcapsules) and CD8+ cells. B – Results 
from co-culture of PEMs with HLA-A02 with CD8+ cells. C- Results from co-culture of PEMs with HLA-A02 
complexed with NV9 peptide with CD8+ cells. D - Results from co-culture of PEMs with HLA-A02 complexed 
with IV9 peptide with CD8+ cells. 
 
As mentioned before, the assay to confirm that PEMs bind to CD8+ T cells was conducted 
with CD8+ cells from three different donors. Figure 3.10 shows the results obtained using CD8+ 
cells from donor I, which was a non-responsive CMV donor. Figure 3.10A shows that the 
percentage of binding when CD8+ cells were co-cultured with PEMs alone was 1.75% and when 
CD8+ cells were co-cultured with PEMs with HLA-A02 molecules was 2.81% (Figure 3.10B). 
Figure 3.10C shows that the percentage of binding was 2.19% when CD8+ cells were cultured 
with PEMs with HLA-A02 molecules complexed with NV9 peptide and Figure 3.10D shows the 
percentage of binding when CD8+ cells were co-cultured with PEMs with HLA-02 molecules 
complexed with IV9 peptide was about 1.18%. 
Similarly, as with the previous section, these results were not expected since it is possible to 
observe a higher percentage of binding when CD8+ cells were co-cultured with PEMs with HLA-
A02 molecules (Figure 3.10B) and besides CD8+ cells were from a non CMV donor it was possible 
to confirm thatCD8+ cells and PEMs form a bond when cells were co-cultured with PEMs with 
HLA-A02 molecules complexed with NV9 peptide (Figure 3.10C) which was not expected. 
Comparing the results from this donor with the results from a CMV positive donor (Figure 3.9), it 
is not possible to see considerable differences (proportionally), which further suggest that PEMs 
are not able to drive antigen-specific responses. 
 
 
 
 
 
C D 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 - Binding between PEMs and CD8 cells analyzed by flow cytometry. In Q2 quadrant 
are the doublets (PEMs+CD8) double stained with biotin FITC and CD8 PE. CD8+ T cells used in co-culture 
were from donor H. A – Results from co-culture of PEMs (just the microcapsules) and CD8+ cells. B – Results 
from co-culture of PEMs with HLA-A02 with CD8+ cells. C- Results from co-culture of PEMs with HLA-A02 
complexed with NV9 peptide with CD8+ cells. D - Results from co-culture of PEMs with HLA-A02 complexed 
with IV9 peptide with CD8+ cells. 
 
The results obtained using the CD8+ cells from the third donor (donor H) are shown in Figure 
3.11. H donor was not responsive to CMV peptide as it was observed in qPCR and ELISA results. 
The percentage of binding when CD8+ cells were co-cultured with PEMs alone was 2.28% (Figure 
3.11A). Figure 3.11B shows that the percentage of binding when CD8+ cells were co-cultured with 
PEMs with HLA-A02 molecules was 3.79% and Figure 3.11C shows that the percentage of 
binding was 3.74% when CD8+ cells were cultured with PEMs with HLA-A02 molecules 
complexed with NV9 peptide. Finally, the percentage of binding when CD8+ cells were co-cultured 
with PEMs with HLA-02 molecules complexed with IV9 peptide was about 2.89% (Figure 3.11D). 
As the results shown before, these results were not expected since it is possible to observe, 
once again, a bigger percentage of binding when CD8+ cells were co-cultured with PEMs with 
A B 
C 
D 
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HLA-A02 molecules (Figure 3.11B) and a link between the cells and microcapsules when cells 
were co-cultured with PEMs with HLA-A02 molecules complexed with NV9 peptide (Figure 3.11C) 
besides cells being from a non CMV donor.  
Considering the results from the three donors, it is also seen (in all donors) that CD8+ cells 
bind to PEMs with HLA-A02 molecules complexed with IV9 peptide (Figures 3.9D, 3.10D and 
3.11D). Considering that only a small percentage (less than 5%) of cells were interacting with 
PEMs, this was not expected because CD8+ cells were isolated from a healthy donor that should 
not respond to the HIV peptide. All these results together confirm that PEMs are not stable and 
are not specific, explaining why they can bind to cells from CMV negative donors and even without 
having a peptide complexed to them. 
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4 Conclusion and Future Perspectives 
 
Cancer is one of the most prevalent diseases of the 21st century and one of the leading 
causes of death around the world. For this reason, it is imperative to try to understand more about 
the disease and especially about the treatments that can fight it. For this purpose, 
immunotherapies such as cancer vaccines are one of the approaches that have been studied in 
the last few decades.  
The main aim of this thesis was to test the capacity of PEMs to activate CD8+ T cells, as a 
possible technology for future therapeutic applications, either as a vaccine or as adjuvant. 
Considering all the results, it is possible to confirm that PEMs can activate T cells when 
complexed with a peptide that T cells where already exposed to.  
In contrast, it is also true that PEMs are unstable microcapsules that can interfere with some 
mechanisms of the cells.  
Since PEMs can only provide the first signal to activate T cells it is relevant to test if the 
microcapsules provide the other two signals. Performing cell co-cultures with IL-2 in the medium 
is a possibility in order to provide the third signal. The second signal could also be provided by 
using antibodies against the co-stimulatory receptors.  
Another improvement to the protocol described here should include the screening of CMV-
positive donors before co-cultures. Like this, it is possible to confirm that the increase of the 
expression of IFN-γ was due to the activation of the cells and not due to another factors.  
Since our collaborators from Germany confirmed the variability of PEMs due to their 
manufacture process in other assays, the microcapsules currently being manufactured show 
increased stability because they present a silica core. These new capsules should also be tested 
using the same procedures and the results compared to the previous ones to confirm which ones 
are more stable and better to perform the next tests.  
The main goal of these microcapsules is to be used as anticancer immunotherapy. To test 
them we need to test the capacity of PEMs bind to cancer antigens and activate T cells against 
these antigens. All these tests should be done in the future.  
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6 Appendixes  
 
Appendix I: Composition of the solutions and reagents used in the work developed  
 
 
Beads buffer: Solution containing 0.5% of BSA (w/v) and 2mM of EDTA, in PBS 1x 
 
Blocking buffer: solution containing 2% of BSA in washing buffer 
 
PBS 1x: Solution containing 1.47 mM of KH2PO4, 4.29 mM of Na2HPO4.7H2O, 137 mM of 
NaCl and mM of KCl, in distilled water (pH=7.4).  
 
Red blood cell lysis 10x: Solution containing 8.02 g of NH4Cl, 0.84 g of NaHCO3, 0.37 g of 
EDTA, in distilled water until 100 mL (pH=7.3). 
 
Washing buffer: Solution containing 0.05% (v/v) of Tween 20 in PBS 1x  
 
  
